Journal of Physiological Sciences (Aug 2023)

Vidarabine, an anti-herpes agent, improves Porphyromonas gingivalis lipopolysaccharide-induced cardiac dysfunction in mice

  • Michinori Tsunoda,
  • Ichiro Matsuo,
  • Yoshiki Ohnuki,
  • Kenji Suita,
  • Misao Ishikawa,
  • Takao Mitsubayashi,
  • Aiko Ito,
  • Yasumasa Mototani,
  • Kenichi Kiyomoto,
  • Akinaka Morii,
  • Megumi Nariyama,
  • Yoshio Hayakawa,
  • Kazuhiro Gomi,
  • Satoshi Okumura

DOI
https://doi.org/10.1186/s12576-023-00873-5
Journal volume & issue
Vol. 73, no. 1
pp. 1 – 12

Abstract

Read online

Abstract In this work, we examined the involvement of type 5 adenylyl cyclase (AC5) in cardiac dysfunction induced in mice given Porphyromonas gingivalis lipopolysaccharide (PG-LPS) at a dose equivalent to the circulating levels in periodontitis (PD) patients. Cardiac function was significantly decreased in mice given PG-LPS compared to the control, but treatment for 1 week with the AC5 inhibitor vidarabine ameliorated the dysfunction. Cardiac fibrosis and myocyte apoptosis were significantly increased in the PG-LPS group, but vidarabine blocked these changes. The PG-LPS-induced cardiac dysfunction was associated with activation of cyclic AMP/Ca2+-calmodulin-dependent protein kinase II signaling and increased phospholamban phosphorylation at threonine 17. These results suggest that pharmacological AC5 inhibition may be a promising approach to treat PD-associated cardiovascular disease.

Keywords